CS1-CAR T Therapy Following Chemotherapy in Treating Patients With Relapsed or Refractory CS1 Positive Multiple Myeloma
NCT03710421
Age 18 +
Sex Both
Phase Phase 1
Third Opinion Trial Synopsis
This study is testing a new treatment for people with multiple myeloma who haven't responded to other treatments or have had their cancer come back. Scientists are trying to change patients' immune cells so they can find and kill the cancer cells using a special virus called CS1. They want to figure out how much of the treatment is safe and effective.
This study is testing a new treatment for people with multiple myeloma who haven't responded to other treatments or have had their cancer come back. Scientists are trying to change patients' immune cells so they can find and kill the cancer cells using a special virus called CS1. They want to figure out how much of the treatment is safe and effective.
Third Opinion AI Generated Synopsis
Trial Summary
This phase I trial studies the side effects and best dose of CS1-chimeric antigen receptor (CAR) T therapy after chemotherapy in treating patients who have CS1 positive multiple myeloma that has come back (relapsed) or does not respond to treatment (refractory). Immune cells can be engineered to kill multiple myeloma cells by inserting a piece of deoxyribonucleic acid (DNA) into the immune cells using a lentiviral vector such as CS1, that allows them to recognize multiple myeloma cells. These engineered immune cells, CS1-CAR T cells, may kill multiple myeloma cells.
This phase I trial studies the side effects and best dose of CS1-chimeric antigen receptor (CAR) T therapy after chemotherapy in treating patients who have CS1 positive multiple myeloma that has come back (relapsed) or does not respond to treatment (refractory). Immune cells can be engineered to kill multiple myeloma cells by inserting a piece of deoxyribonucleic acid (DNA) into the immune cells using a lentiviral vector such as CS1, that allows them to recognize multiple myeloma cells. These engineered immune cells, CS1-CAR T cells, may kill multiple myeloma cells.
from ClinicalTrials.gov
Locations & Contact
Fill out the form and to let the Multiple Myeloma Research Foundation know you are interested in this trial.
Contacts:
